JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $5.30.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Tuerkcan is an analyst with an average return of -1.7% and a 34.29% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Exelixis, Solid Biosciences, and Relay Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Solid Biosciences with a $16.29 average price target, implying a 207.36% upside from current levels. In a report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $16.00 price target.
The company has a one-year high of $15.05 and a one-year low of $2.88. Currently, Solid Biosciences has an average volume of 568.4K.
Read More on SLDB:
- Solid Biosciences price target raised to $16 from $15 at Chardan
- Solid Biosciences 35.74M share Spot Secondary priced at $4.03
- Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial
- Biotech Alert: Searches spiking for these stocks today
- Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue